1. Guidance on E14 Clinical Evaluation of QT/ QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; Availability;International Conference on Harmonisation;Notice. Fed Regist,2005
2. Guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability;International Conference on Harmonisation;Notice. Fed Regist,2005
3. Drug-induced spatial dispersion of repolarization;Antzelevitch;Cardiol. J.,2008
4. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines;Lu;Br. J. Pharmacol.,2008
5. Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives;Shah;Br. J. Pharmacol.,2009